Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:EMBCNYSE:ENOVNASDAQ:LIVNNASDAQ:NVCR On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeEMBCEmbecta$9.91+1.2%$11.67$9.75▼$21.48$579.17M1.13474,389 shs841,294 shsENOVEnovis$32.94+3.6%$33.29$29.13▼$49.83$1.88B1.71823,028 shs1.99 million shsLIVNLivaNova$46.30+0.8%$39.56$32.48▼$57.35$2.52B0.9647,167 shs775,311 shsNVCRNovoCure$16.90-0.6%$17.36$14.17▼$34.13$1.88B0.741.17 million shs1.12 million shsBeginner's Guide To Retirement StocksEnter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceEMBCEmbecta0.00%-7.82%-18.42%-29.87%-21.30%ENOVEnovis0.00%+1.50%-3.81%-10.57%-31.41%LIVNLivaNova0.00%+6.39%+4.29%+24.12%-13.92%NVCRNovoCure0.00%-9.91%-2.19%-16.21%-20.93%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationEMBCEmbecta4.8351 of 5 stars3.25.03.30.02.23.33.8ENOVEnovis2.2363 of 5 stars3.41.00.00.01.11.71.9LIVNLivaNova2.8095 of 5 stars3.53.00.00.02.01.71.3NVCRNovoCure3.5853 of 5 stars3.32.00.04.51.81.70.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceEMBCEmbecta 2.33Hold$19.3395.09% UpsideENOVEnovis 2.80Moderate Buy$58.0076.08% UpsideLIVNLivaNova 3.00Buy$59.2928.05% UpsideNVCRNovoCure 2.67Moderate Buy$32.8394.28% UpsideCurrent Analyst Ratings BreakdownLatest EMBC, LIVN, ENOV, and NVCR Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/23/2025EMBCEmbectaBTIG ResearchSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price TargetBuy ➝ Buy$25.005/23/2025EMBCEmbectaMizuhoSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$15.00 ➝ $13.005/20/2025LIVNLivaNovaWolfe ResearchSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradePeer Perform ➝ Outperform$60.005/14/2025ENOVEnovisCanaccord Genuity GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$75.00 ➝ $70.005/13/2025LIVNLivaNovaNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$64.00 ➝ $64.005/9/2025ENOVEnovisJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetMarket Outperform ➝ Market Outperform$62.00 ➝ $55.005/9/2025ENOVEnovisNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$64.00 ➝ $57.005/8/2025LIVNLivaNovaBarclaysSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetEqual Weight ➝ Equal Weight$56.00 ➝ $55.005/8/2025LIVNLivaNovaRobert W. BairdSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$55.00 ➝ $61.004/23/2025NVCRNovoCurePiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$42.00 ➝ $34.004/16/2025NVCRNovoCureWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$29.00 ➝ $27.00(Data available from 6/9/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookEMBCEmbecta$1.08B0.54$2.29 per share4.32($13.23) per share-0.75ENOVEnovis$2.15B0.88$4.80 per share6.86$62.66 per share0.53LIVNLivaNova$1.28B1.98$4.15 per share11.15$23.72 per share1.95NVCRNovoCure$621.71M3.03N/AN/A$3.39 per share4.99Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateEMBCEmbecta$78.30M$0.909.913.230.785.25%-19.22%11.92%8/8/2025 (Estimated)ENOVEnovis-$33.26M-$13.95N/A10.33N/A-5.95%4.39%2.80%8/6/2025 (Estimated)LIVNLivaNova$17.55M-$4.09110.2414.75N/A1.91%13.81%7.07%7/30/2025 (Estimated)NVCRNovoCure-$207.04M-$1.51N/AN/AN/A-25.93%-41.48%-12.74%7/24/2025 (Estimated)Latest EMBC, LIVN, ENOV, and NVCR EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/9/2025Q2 2025EMBCEmbecta$0.66$0.70+$0.04$0.40$261.77 million$259.00 million5/8/2025Q1 2025ENOVEnovis$0.74$0.81+$0.07-$0.98$558.80 million$558.83 million4/24/2025Q1 2025NVCRNovoCure-$0.47-$0.31+$0.16-$0.31$147.57 million$154.99 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthEMBCEmbecta$0.606.05%N/A66.67%N/AENOVEnovisN/AN/AN/AN/AN/ALIVNLivaNovaN/AN/AN/AN/AN/ANVCRNovoCureN/AN/AN/AN/AN/ALatest EMBC, LIVN, ENOV, and NVCR DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date5/5/2025EMBCEmbectaquarterly$0.154.51%5/28/20255/28/20256/13/2025(Data available from 1/1/2013 forward)Compare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioEMBCEmbectaN/A2.241.67ENOVEnovis0.402.271.12LIVNLivaNova0.463.372.87NVCRNovoCure0.271.491.44Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipEMBCEmbecta93.83%ENOVEnovis98.45%LIVNLivaNova97.64%NVCRNovoCure84.61%Insider OwnershipCompanyInsider OwnershipEMBCEmbecta0.42%ENOVEnovis2.70%LIVNLivaNova0.29%NVCRNovoCure6.29%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableEMBCEmbecta1,90058.44 million57.89 millionOptionableENOVEnovis6,80057.12 million55.49 millionOptionableLIVNLivaNova2,90054.53 million54.15 millionOptionableNVCRNovoCure1,320111.49 million101.40 millionOptionableEMBC, LIVN, ENOV, and NVCR HeadlinesRecent News About These CompaniesNovoCure Limited (NASDAQ:NVCR) Receives $32.83 Average Price Target from AnalystsJune 7 at 2:43 AM | americanbankingnews.comWedbush Estimates NovoCure's FY2026 Earnings (NASDAQ:NVCR)June 7 at 1:45 AM | americanbankingnews.comNVCR Stock Dips Despite Positive OS Data From Phase 3 PANOVA-3 TrialJune 6 at 1:30 PM | zacks.comWhat is Wedbush's Estimate for NovoCure FY2026 Earnings?June 5, 2025 | marketbeat.comNovoCure (NASDAQ:NVCR) Sees Strong Trading Volume - Still a Buy?June 4, 2025 | marketbeat.comNovoCure Limited (NASDAQ:NVCR) Given Consensus Rating of "Moderate Buy" by AnalystsJune 4, 2025 | marketbeat.comNovoCure (NASDAQ:NVCR) Shares Down 8.2% - Should You Sell?June 3, 2025 | marketbeat.comResults From the Phase 3 PANOVA-3 Trial of Novocure’s Tumor Treating Fields (TTFields) Therapy for Pancreatic Cancer to be Presented at 2025 ASCO Annual MeetingJune 2, 2025 | businesswire.comNovocure data support pancreatic cancer approval, says Wells FargoJune 2, 2025 | msn.comNovocure study shows improved pancreatic cancer survivalJune 2, 2025 | massdevice.comNovoCure's Tumor Treating Fields Boost One-Year And Pain-Free Survival In Pancreatic Cancer TrialJune 2, 2025 | aol.comZai Lab and Novocure Announce Results From the Phase 3 PANOVA-3 Trial of Tumor Treating Fields (TTFields) Therapy for Pancreatic Cancer to be Presented at 2025 ASCO Annual MeetingMay 31, 2025 | businesswire.comUBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Lowers Stock Holdings in NovoCure Limited (NASDAQ:NVCR)May 29, 2025 | marketbeat.com1 Stock Down 35% This Year You'll Regret Not Buying on the Dip, According to Wall StreetMay 28, 2025 | msn.comNovocure Announces Upcoming Investor EventsMay 27, 2025 | finance.yahoo.comNovoCure Limited (NASDAQ:NVCR) Shares Sold by Two Sigma Investments LPMay 25, 2025 | marketbeat.comNovoCure Limited (NASDAQ:NVCR) Shares Sold by Voloridge Investment Management LLCMay 24, 2025 | marketbeat.comTwo Sigma Advisers LP Trims Stake in NovoCure Limited (NASDAQ:NVCR)May 24, 2025 | marketbeat.comNovoCure: Loading Up On Growth CatalystsMay 24, 2025 | seekingalpha.comBNP Paribas Financial Markets Sells 147,371 Shares of NovoCure Limited (NASDAQ:NVCR)May 24, 2025 | marketbeat.comNovoCure Limited (NASDAQ:NVCR) Holdings Boosted by Millennium Management LLCMay 23, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeEMBC, LIVN, ENOV, and NVCR Company DescriptionsEmbecta NASDAQ:EMBC$9.91 +0.12 (+1.23%) Closing price 04:00 PM EasternExtended Trading$10.04 +0.13 (+1.26%) As of 04:20 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Embecta Corp., a medical device company, focuses on the provision of various solutions to enhance the health and wellbeing of people living with diabetes. Its products include pen needles, syringes, and safety injection devices, as well as digital applications to assist people with managing patient's diabetes. The company primarily sells its products to wholesalers and distributors in the United States and internationally. Embecta Corp. was founded in 1924 and is headquartered in Parsippany, New Jersey.Enovis NYSE:ENOV$32.94 +1.15 (+3.62%) Closing price 03:59 PM EasternExtended Trading$32.91 -0.03 (-0.09%) As of 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Enovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions worldwide. It also manufactures and distributes medical devices which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company operates through Prevention and Recovery, and Reconstructive segments. Its Prevention and Recovery segment offers orthopedic solutions and recovery sciences including rigid and soft orthopedic bracing, hot and cold therapy, bone growth stimulators, vascular therapy systems and compression garments, therapeutic shoes and inserts, electrical stimulators management, and physical therapy products which are used by orthopedic specialists, surgeons, primary care physicians, pain management specialists, physical therapists, podiatrists, chiropractors, athletic trainers, and other healthcare professionals. The company's Reconstructive segment operates surgical implant business, which includes a suite of reconstructive joint products for the hip, knee, shoulder, elbow, foot, ankle, and finger, as well as surgical productivity tools. The company distributes its products through independent distributors and directly under the ESAB and DJO brands. Enovis Corporation was formerly known as Colfax Corporation. The company was founded in 1995 and is headquartered in Wilmington, Delaware.LivaNova NASDAQ:LIVN$46.30 +0.35 (+0.76%) Closing price 04:00 PM EasternExtended Trading$46.30 +0.01 (+0.01%) As of 04:21 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products. The Neuromodulation segment designs, develops, markets, and sells VNS Therapy System, an implantable pulse generator and connective lead that stimulates the vagus nerve; difficult-to-treat depression and drug-resistant epilepsy devices. The Advanced Circulatory Support segment develops, produces, and sells temporary life support products. It serves perfusionists, neurologists, neurosurgeons, and other physicians, as well as hospitals, other medical institutions, and healthcare providers. The company sells its products through direct sales representatives and independent distributors. LivaNova PLC was incorporated in 2015 and is headquartered in London, the United Kingdom.NovoCure NASDAQ:NVCR$16.90 -0.10 (-0.59%) Closing price 04:00 PM EasternExtended Trading$16.93 +0.03 (+0.18%) As of 04:31 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, Japan, Greater China, and internationally. The company's TTFields devices include Optune Gio and Optune Lua. It also has ongoing clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. NovoCure Limited was incorporated in 2000 and is headquartered in Saint Helier, Jersey. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Science Applications International Is a Wicked Hot Buy in June Why Unity Software May Be the AI Breakout No One Saw Coming Tesla Stock Dips to Buy Zone—Robotaxi Catalyst Ahead? Is Lululemon’s 18% Selloff Overdone? Analysts Say Yes MarketBeat Week in Review – 06/02 - 06/06 This Banking Giant Just Got a $90 Price Target Upgrade Broadcom Slides on Solid Earnings, AI Outlook Still Strong The Market’s Silent Warning: What Bonds and Gold Reveal Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
